<div class="container">

<table style="width: 100%;"><tr>
<td>drugdevelopR</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Utility based optimal phase II/III drug development planning</h2>

<h3>Description</h3>

<p>The drugdevelopR package enables utility based planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules. The assumed true treatment effects can be assumed fixed (planning is then also possible via user friendly R Shiny App: <a href="https://web.imbi.uni-heidelberg.de/drugdevelopR/">drugdevelopR</a>) or modelled by a prior distribution. The R Shiny application <a href="https://web.imbi.uni-heidelberg.de/prior/">prior</a> visualizes the prior distributions used in this package. Fast computing is enabled by parallel programming.
</p>


<h3>Usage</h3>

<pre><code class="language-R">drugdevelopR()
</code></pre>


<h3>drugdevelopR package and R Shiny App</h3>

<p>The drugdevelopR package provides the functions to plan optimal phase II/III drug development programs with
</p>

<ul>
<li>
<p> time-to-event endpoint (<code>optimal_tte</code>),
</p>
</li>
<li>
<p> binary endpoint (<code>optimal_binary</code>) and
</p>
</li>
<li>
<p> normally distributed endpoint (<code>optimal_normal</code>),
</p>
</li>
</ul>
<p>where the treatment effect is assumed fixed or modelled by a <a href="https://web.imbi.uni-heidelberg.de/prior/">prior</a>. In these settings, optimal phase II/III drug development planning with fixed assumed treatment effects can also be done with the help of the R Shiny application <a href="https://web.imbi.uni-heidelberg.de/basic/">basic</a>. Extensions to the basic setting are
</p>

<ul>
<li>
<p> optimal planning of programs including methods for discounting of phase II results (function: <code>optimal_bias</code>, App: <a href="https://web.imbi.uni-heidelberg.de/bias/">bias</a>),
</p>
</li>
<li>
<p> optimal planning of programs with several phase III trials (function: <code>optimal_multitrial</code>, App: <a href="https://web.imbi.uni-heidelberg.de/multitrial/">multitrial</a>) and
</p>
</li>
<li>
<p> optimal planning of programs with multiple arms (function: <code>optimal_multiarm</code>, App: <a href="https://web.imbi.uni-heidelberg.de/multiarm/">multiarm</a>).
</p>
</li>
</ul>
<p>The R Shiny App <a href="https://web.imbi.uni-heidelberg.de/drugdevelopR/">drugdevelopR</a> serves as homepage, navigating the different parts of drugdevelopR via links.
</p>


<h3>References</h3>

<p>Kirchner, M., Kieser, M., Goette, H., &amp; Schueler, A. (2016). Utility-based optimization of phase II/III programs. Statistics in Medicine, 35(2), 305-316.
</p>
<p>Preussler, S., Kieser, M., and Kirchner, M. (2019). Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed. Biometrical Journal, 61(2), 357-378.
</p>
<p>Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. Submitted to peer-review journal.
</p>
<p>Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal designs for multi-arm Phase II/III drug development programs. Submitted to peer-review journal.
</p>


</div>